Search

Displaying results 9581 - 9590 of 10000 in total
  1. Drug

    ALMB-0166

    go.drugbank.com/drugs/DB17937
    Investigational

    It was granted FDA orphan designation in November 2018.[L47067]

  2. Drug

    AGuIX

    go.drugbank.com/drugs/DB18189
    Investigational

    AGuIX is an investigational brand product consisting of a polysiloxane matrix and gadolinium chelates.

  3. Drug

    Chimeric antigen receptor T-cells

    go.drugbank.com/drugs/DB22146
    Investigational

    Chimeric Antigen Receptor T-cells is under investigation in clinical trial NCT05225363 (Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian

  4. Drug

    Retaspimycin

    go.drugbank.com/drugs/DB05626
    Investigational

  5. Drug

    SB-743921

    go.drugbank.com/drugs/DB05546
    Investigational

  6. Drug

    Teverelix

    go.drugbank.com/drugs/DB05624
    Investigational

    A synthetic decapeptide, water-soluble Gonadotropin-releasing hormone antagonist. It has reached phase II clinical trials.

  7. Drug

    Urelumab

    go.drugbank.com/drugs/DB12077
    Investigational

    Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. … The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with

  8. Drug

    MKC-1

    go.drugbank.com/drugs/DB05608
    Investigational

  9. Drug

    IPH 1101

    go.drugbank.com/drugs/DB05754
    Experimental

    IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset. IPH 1101 is the most advanced drug candidate of the γδ T cell platform

  10. Drug

    Vadimezan

    go.drugbank.com/drugs/DB06235
    Investigational